RT Journal Article
SR Electronic
T1 A Novel Primer Probe Set for Detection of SARS-CoV-2 by Sensitive Droplet Digital PCR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.03.20224972
DO 10.1101/2020.11.03.20224972
A1 Wang, Fang
A1 Pervaiz, Umar
A1 Tian, Hongwei
A1 Mariam, Algahdary Omar Ahmed Omar
A1 Hamid, Mahasin Abdallah Mohammed
A1 Wang, Degui
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.03.20224972.abstract
AB Background The current increase in the spread of (SARS-CoV-2) critically needs a multitarget diagnostic assays to promote analytical sensitivity to facilitate the public health actions.Objective The aim of this study was to develop a new primer-probe set targeting N gene of SARS-CoV-2 to improve the sensitivity for detection of COVID-19(Corona Virus Disease 2019)in multiplex rRT-PCR (Reversetranscript Realtime PCR) and ddPCR (Droplet Digital PCR).Results We designed primers/probes set N(LZU3) targeting the N gene of 2019-nCov and proved its sensitivity in both rRT-PCR and ddPCR. When the quantity of template was 105 copies/reaction, the mean Ct value of N(LZU3) was 32.563, the detection rate was 91.7%. If the quantity of template was 52.5 copies/reaction, the mean Ct value of N(LZU3) was 33.835, and the detection rate was 83.3%, which were similar with that of N(CDC) and N(USA). The calculated lower limit of detection (LOD) of the new primer-probe set N(LZU3) used in rRT-PCR was 118 copies/reaction. We also did one-step ddPCR for detection the same serial dilution of RNA template. It shows good linearity for primer/probe sets N(LZU3). The calculated lower limit of detection (LOD) of N(LZU3) was 22.4 copies/reaction, which was 1.12 copies/ul.Conclusion The novel primer-probe set(LZU3) targeting N gene of SARS-CoV-2 could be both used in rRT-PCR and ddPCR with better sensitivity, furthermore, ddPCR method had higer sensitivity than rRT-PCR, hence it could significantly improve SARS-CoV-2 detection efficiency in low virus load and asymptomatic infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Natural Science Foundation of China 81902364, Special Funding for Open and Shared Large-Scale Instruments and Equipments of Lanzhou University LZU-GXJJ-2019C011, and the Fundamental Research Funds for the Central Universities(lzujbky-2020-sp16).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:School of Basic medical SciencesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in the manuscript are available.